HUTCHMED (NASDAQ:HCM) Downgraded to Hold at StockNews.com

StockNews.com downgraded shares of HUTCHMED (NASDAQ:HCM) from a buy rating to a hold rating in a research note published on Thursday.

HUTCHMED Stock Performance

HCM opened at $18.94 on Thursday. The business’s 50-day moving average price is $18.53 and its two-hundred day moving average price is $16.96. HUTCHMED has a 1 year low of $11.93 and a 1 year high of $21.92. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.72 and a quick ratio of 2.60.

Institutional Investors Weigh In On HUTCHMED

Institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. boosted its stake in shares of HUTCHMED by 353.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,593 shares of the company’s stock worth $65,000 after buying an additional 2,801 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in HUTCHMED by 70.5% during the first quarter. Russell Investments Group Ltd. now owns 18,179 shares of the company’s stock worth $304,000 after acquiring an additional 7,515 shares in the last quarter. BNP Paribas Financial Markets boosted its position in HUTCHMED by 54.9% during the first quarter. BNP Paribas Financial Markets now owns 42,926 shares of the company’s stock valued at $721,000 after purchasing an additional 15,221 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its stake in HUTCHMED by 2.5% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 57,010 shares of the company’s stock valued at $958,000 after purchasing an additional 1,388 shares in the last quarter. Finally, Baillie Gifford & Co. increased its position in shares of HUTCHMED by 7.2% during the 4th quarter. Baillie Gifford & Co. now owns 144,969 shares of the company’s stock worth $2,625,000 after purchasing an additional 9,694 shares during the last quarter. Institutional investors own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.